A decision analysis of long-term lithium treatment and the risk of renal failure

Acta Psychiatrica Scandinavica

Volumn 126, Issue 3, 2012, Pages 186-197

  Werneke, U ^a   Ott, M ^b   Renberg, E Salander ^a   Taylor, D ^c   Stegmayr, B ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SUNDERBY HOSPITAL   (Sweden)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Bipolar disorder; Decision analysis; End stage renal disease; Lithium; Suicide

Indexed keywords

LITHIUM;

ANTICONVULSANT THERAPY; ARTICLE; BIPOLAR DISORDER; DEATH; DECISION TREE; DISEASE COURSE; HUMAN; KIDNEY FAILURE; LONG TERM CARE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; SUICIDE;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LITHIUM CARBONATE; RECURRENCE; SUICIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865103123     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2012.01847.x     Document Type: Article

References (62)

1. Young AH, Hammond JM. Lithium in mood disorders: increasing evidence base, declining use? Br J Psychiatry 2007;191:474-476.
2. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949;2:349-352.
3. Moncrieff J. Lithium: evidence reconsidered. Br J Psychiatry 1997;171:113-119.
4. Schou M, Vestergaard P. Lithium and the kidney scare. Psychosomatics 1981;22:92.
5. Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs 2009;23:397-418.
6. Bendz H, Schön S, Attman PO, Aurell M. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int 2010;77:219-224.
7. Stahl SM. The prescriber's guide. Stahl's essential psychopharmacology, 4th edn. New York, NY: Cambridge University Press, 2011.
8. TreeAge Pro 2009 and 2011 (Williamstown, Massachusetts).
9. Baldessarini RJ, Tondo L. Suicidal risks during treatment of bipolar disorder patients with lithium versus anticonvulsants. Pharmacopsychiatry 2009;42:72-75.
10. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006;8:625-639.
11. Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44years' follow-up. Arch Suicide Res 2005;9:279-300.
12. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005;162:1805-1819.
13. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003;290:1467-1473.
14. Søndergård L, Lopez AG, Andersen PK, Kessing LV. Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide. Bipolar Disord 2008;10:87-94.
15. Müller-Oerlinghausen B, Müser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992;25:261-269.
16. Geddes JR, Goodwin GM, Rendell J et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010;375:385-395.
17. Licht RW, Nielsen JN, Gram LF, Vestergaard P, Bendz H. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6 trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 2010;12:483-493.
18. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011;199:57-63.
19. Kessing LV, Hellmund G, Andersen PK. An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorder. J Psychopharmacol 2012;26:644-652.
20. Kulhara P, Basu D, Mattoo SK, Sharan P, Chopra R. Lithium prophylaxis of recurrent bipolar affective disorder: long-term outcome and its psychosocial correlates. J Affect Disord 1999;54:87-96.
21. Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR. Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. J Psychopharmacol 2009;23:574-591.
22. Bassilios N, Martel P, Godard V et al. Monitoring of glomerular filtration rate in lithium-treated outpatients-an ambulatory laboratory database surveillance. Nephrol Dial Transplant 2008;23:562-565.
23. Lepkifker E, Sverdlik A, Iancu I, Ziv R, Segev S, Kotler M. Renal insufficiency in long-term lithium treatment. J Clin Psychiatry 2004;65:850-856.
24. Presne C, Fakhouri F, Noël LH et al. Lithium-induced nephropathy: rate of progression and prognostic factors. Kidney Int 2003;64:585-592.
25. Quinn RR, Naimark DM, Oliver MJ, Bayoumi AM. Should hemodialysis patients with a trial fibrillation undergo systemic anticoagulation? A cost-utility analysis. Am J Kidney Dis 2007;50:421-432.
26. Sennfalt K, Magnusson M, Carlsson P. Comparison of hemodialysis and peritoneal dialysis - a cost utility analysis. Perit Dial Int 2002;22:39-47.
27. König HH, Günther OH, Angermeyer MC, Roick C. Utility assessment in patients with mental disorders: validity and discriminative ability of the time trade-off method. Pharmacoeconomics 2009;27:405-419.
28. Hayhurst H, Palmer S, Abbott R, Johnson T, Scott J. Measuring health-related quality of life in bipolar disorder: relationship of the EuroQol (EQ-5D) to condition-specific measures. Qual Life Res 2006;15:1271-1280.
29. Bennett KJ, Torrance GW, Boyle MH, Guscott R. Cost-utility analysis in depression: the McSad utility measure for depression health states. Psychiatr Serv 2000;51:1171-1176.
30. Schaffer A, Levitt AJ, Hershkop SK, Oh P, MacDonald C, Lanctot K. Utility scores of symptom profiles in major depression. Psychiatry Res 2002;110:189-197.
31. Sobocki P, Ekman M, Ovanfors A, Khandker R, Jönsson B. The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder. Int J Clin Pract 2008;62:623-632.
32. Revicki DA, Hanlon J, Martin S, Gyulai L et al. Patient-based utilities for bipolar disorder-related health states. J Affect Disord 2005;87:203-210.
33. Kassirer JP, Pauker SG, as quoted in Petiti DB. Meta-analysis, decision analysis and cost-effectiveness analysis. New York, NY: Oxford University Press, 1994.
34. Bendz H, Sjödin I, Aurell M. Renal function on and off lithium in patients treated with lithium for 15years or more. A controlled, prospective lithium-withdrawal study. Nephrol Dial Transplant 1996;11:457-460.
35. Markowitz GS, Radhakrishnan J, Kambham N, Valeri AM, Hines WH, D'Agati VD. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 2000;11:1439-1448.
36. Tohen M, Greil W, Calabrese JR et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162:1281-1290.
37. Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010;197:266-271.
38. National Institute for Health and Clinical Excellence. 2006. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. NICE clinical guideline No 38, issue date 1 July. http://www.nice.org.uk/nicemedia/pdf/CG38niceguideline.pdf. Last accessed 13 December 2011.
39. Medsafe. New Zealand Medicines and Medical Devices Safety Authority. Renal dangers associated with long-term lithium use. Prescriber Update Articles. http://www.medsafe.govt.nz/profs/puarticles/renaldanagerssept10.htm Last accessed 13 December 2011.
40. Marangell LB, Dennehy EB, Wisniewski SR et al. Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BD. J Clin Psychiatry 2008;69:916-922.
41. Smith EG, Søndergård L, Lopez AG, Andersen PK, Kessing LV. Association between consistent purchase of anticonvulsants or lithium and suicide risk: a longitudinal cohort study from Denmark, 1995-2001. J Affect Disord 2009;117:162-167.
42. Gibbons RD, Hur K, Brown CH, Mann HH. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry 2009;66:1354-1360.
43. Oquendo MA, Galvalvy HC, Currier D. Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behaviour. Am J Psychiatry 2011;168:1050-1056.
44. Soares-Weiser K, Bravo Vergel Y et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 2007;11:iii-iv, ix-206.
45. Chisholm D, van Ommeren M, Ayuso-Mateos JL, Saxena S. Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder. Br J Psychiatry 2005;187:559-567.
46. Kessing LV, Søndergård L, Kvist K, Andersen PK. Adherence to lithium in naturalistic settings: results from a nationwide pharmacoepidemiological study. Bipolar Disord 2007;9:730-736.
47. Schumann C, Lenz G, Berghöfer A, Müller-Oerlinghausen B. Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients. Psychiatry Res 1999;89:247-257.
48. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996;153:993-1000.
49. Licht RW, Vestergaard P, Rasmussen NA, Jepsen K, Brodersen A, Hansen PE. A lithium clinic for bipolar patients: 2-year outcome of the first 148 patients. Acta Psychiatr Scand 2001;104:387-790.
50. Chan HH, Wing Y, Su R, Van Krevel C, Lee S. A control study of the cutaneous side effects of chronic lithium therapy. J Affect Disord 2000;57:107-113.
51. Szalat A, Mazeh H, Freund HR. Lithium-associated hyperparathyroidism: report of four cases and review of the literature. Eur J Endocrinol 2009;160:317-323.
52. Bendz H, Sjödin I, Toss G, Berglund K. Hyperparathyroidism and long-term lithium therapy--a cross-sectional study and the effect of lithium withdrawal. J Intern Med 1996;240:357-365.
53. Roberts CG, Ladenson PW. Hypothyroidism. Lancet 2004;363:793-803.
54. van Melick EJ, Wilting I, Meinders AE, Egberts TC. Prevalence and determinants of thyroid disorders in elderly patients with affective disorders: lithium and nonlithium patients. Am J Geriatr Psychiatry 2010;18:395-403.
55. Frye MA, Yatham L, Ketter TA et al. Depressive relapse during lithium treatment associated with increased serum thyroid- stimulating hormone: results from two placebo-controlled bipolar I maintenance studies. Acta Psychiatr Scand 2009;120:10-13.
56. Tomson T, Battino D, Bonizzoni E et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-617.
57. Koenig SA, Buesing D, Longin E et al. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 2006;47:2027-2031.
58. Gerstner T, Büsing D, Bell N et al. Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol 2007;42:39-48.
59. Seo HJ, Chiesa A, Lee SJ et al. Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. Clin Neuropharmacol 2011;34:39-47.
60. Ketter TA, Citrome L, Wang PW, Culver JL, Srivastava S. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? Acta Psychiatr Scand 2011;123:175-189.
61. Jefferson JW. A clinician's guide to monitoring kidney function in lithium-treated patients. J Clin Psychiatry 2010;71:1153-1157.
62. Taylor D, Meader N, Bird V, Pilling S, Creed F, Goldberg D. Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analyses of safety and efficacy. Br J Psychiatry 2011;198:179-188.